Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 17.

Journal Article

Abdulla, D. S. Y., Nogova, L., Riedel, R., Scheftler, M., Fischer, R. N., Michels, S., Heydt, C., Ihle, M. A., Fassunke, J., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2018). NTRK1/2/3 gene rearrangements define a new and clinically actionable molecular subset of oncogene-driven cancers. Oncol. Res. Treat., 41. S. 293 - 294. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., Abdulla, D., Michels, S., Nogova, L., Brandes, V, Scheffler, M., Schaeffer, S., Scheel, A., Thurat, M., Vehreschild, M., Thomas, R., von Bergwelt-Baildon, M., Buettner, R. and Wolf, J. (2016). Bioluma: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer - A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response to immune checkpoint inhibition. Oncol. Res. Treat., 39. S. 92 - 94. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., George, J., Schaefer, S., Scheel, A., Schloesser, H., Vehreschild, M., von Bergwelt-Baildon, M., Nogova, L., Abdulla, D. S. Y., Michels, S., Riedel, R., Scheffler, M., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kambartel, K., Kern, J., Kopp, H-G, Neukirchen, J., Overbeck, T. R., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Buettner, R., Thomas, R. and Wolf, J. (2018). BIOLUMA: Biomarkers for nivolumab and evaluation of nivolumab plus ipilimumab in lung cancer. Oncol. Res. Treat., 41. S. 270 - 272. BASEL: KARGER. ISSN 2296-5262

Fischer, R. N., George, J., Scheel, A., Schloesser, H., Brossart, P., Engel-Riedel, W., Griesinger, F., Grohe, C., Kern, J. K., Panse, J., Sebastian, M., Serke, M., Wiewrodt, R., Michels, S., Nogova, L., Riedel, R., Weber, J-P., Buettner, R., Thomas, R. and Wolf, J. (2022). BIOLUMA: A phase II trial of nivolumab in combination with ipilimumab to evaluate efficacy and safety in lung cancer and to evaluate biomarkers predictive for response - results from the NSCLC cohort. Ann. Oncol., 33 (7). S. S1025 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Fischer, R. N., Scheel, A. H., Rothschild, S., I, Schloesser, H. A., Wolf, J., Buettner, R., Ansen, S. and von Bergwelt-Baildon, M. (2015). Tumor-infiltrating B lymphocytes characterized by CD79a and MUM1 independently predict outcome in patients with non-small cell lung cancer. Oncol. Res. Treat., 38. S. 13 - 14. BASEL: KARGER. ISSN 2296-5262

Glaser, M., Von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Wompner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A. K., Fischer, R. N., Riedel, R., Weber, J-P., Hahne, S., Merkelbach-Bruse, S., Buttner, R., Wolf, J. and Scheffler, M. (2022). The biological effect of small-scale ROS1 aberrations: An in silico analysis. Ann. Oncol., 33 (7). S. S1327 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Glaser, M., von Levetzow, C., Michels, S., Nogova, L., Katzenmeier, M., Woempner, C., Schmitz, J., Bitter, E., Terjung, I., Passmann, E., Schaufler, D., Eisert, A., Fischer, R. N., Riedel, R., Hahne, S., Merkelbach-Bruse, S., Buettner, R., Wolf, J. and Scheffler, M. (2022). Small-scale ROS1 aberrations: Functional impact and therapeutic potential. Ann. Oncol., 33 (8). S. S1386 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Holzem, A., Nogova, L., Ihle, M. A., Woempner, C., Bitter, E., Michels, S., Fischer, R. N., Kron, A., Gerigk, U., Kern, J., Kaminsky, B., Randerath, W. J., Lorenz, J., Kambartel, K., Merkelbach-Bruse, S., Buttner, R., Scheffler, M. and Wolf, J. (2018). Co-occurrence of targetable aberrations in non-small cell lung cancer patients harboring MAP2K1 mutations. Oncol. Res. Treat., 41. S. 250 - 251. BASEL: KARGER. ISSN 2296-5262

Kron, A., Scheffler, M., Ihle, M., Michels, S., Sueptitz, J., Prang, D., Jakobs, F., Nogova, L., Fischer, R. N., Eisert, A. K., Riedel, R., Kron, F., Hillmer, A., Loges, S., Merkelbach-Bruse, S., Buettner, R. and Wolf, J. (2022). EGFR exon 20 insertions in non-small cell lung cancer (NSCLC): Impact of TP53 mutation status and value of immune checkpoint blockade (ICB). Ann. Oncol., 33 (7). S. S1006 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Michels, S., Westphal, T., Nogova, L., Scheffler, M., Deschler-Baier, B., Sebastian, M., Schuler, M., Wermke, M., Abdulla, D. S. Y., Fischer, R. N., Koleczko, S., Kron, A., Pinto, A., Riedel, R., Weber, J. -P., Fassunke, J., Merkelbach-Bruse, S., Haverkamp, H., Hellmich, M., Buettner, R. and Wolf, J. (2020). EATON: A phase I dose-escalation trial of nazartinib (EGF816) and trametinib in EGFR-mutant non-small cell lung cancer (NSCLC) - preliminary data. Oncol. Res. Treat., 43 (SUPPL 4). S. 148 - 149. BASEL: KARGER. ISSN 2296-5262

Nogova, L., Malchers, F., Zadoyan, G., Hillmer, A., Merkelbach-Bruse, S., Riedel, R., Michels, S., Masouleh, Kharabi B., De Porre, P., Santiago-Walker, A., Scheffler, M., Fischer, R. N., Abdulla, D. S. Y., Thomas, R., Buettner, R. and Wolf, J. (2018). FIND trial: a phase II study to evaluate the efficacy of the FGFR-inhibitor erdafitinib in FGFR-mutated and - translocated squamous NSCLC (trial in progress). Oncol. Res. Treat., 41. S. 294 - 295. BASEL: KARGER. ISSN 2296-5262

Riedel, R., Michels, S., Heydt, C., Nogova, L., Fischer, R. N., Abdulla, D. S. Y., Scheffler, M., Merkelbach-Bruse, S., Kobe, C., Schaefer, S., Buettner, R. and Wolf, J. (2018). Durable response to crizotinib in a patient with lung adenocarcinoma harbouring low-level MET amplification but strong MET expression. Oncol. Res. Treat., 41. S. 295 - 297. BASEL: KARGER. ISSN 2296-5262

Scheel, A. H., Dietel, M., Heukamp, L. C., Joehrens, K., Kirchner, T., Reu, S., Rueschoff, J., Schildhaus, H. U., Schirmacher, P., Tiemann, M., Warth, A., Weichert, W., Fischer, R. N., Wolf, J. and Buettner, R. (2016). Predictive PD-L1 immunohistochemistry for non-small cell lung cancer. Current state of the art and experiences of the first German harmonization study. Pathologe, 37 (6). S. 557 - 568. HEIDELBERG: SPRINGER HEIDELBERG. ISSN 1432-1963

Scheffler, M., Abdulla, D. S. Y., Koleczko, S., Nogova, L., Michels, S., Fischer, R. N., Riedel, R., Woempner, C., Holzem, A., Thurat, M. and Wolf, J. (2018). Pharmacokinetics of nintedanib in combination with everolimus in patients with solid tumors - Results from the phase I BARIS trial. Oncol. Res. Treat., 41. S. 309 - 310. BASEL: KARGER. ISSN 2296-5262

Scheffler, M., Nogova, L., Michels, S., Holzem, A., Chanra, T., Abdulla, D. S. Y., Koleczko, S., Merkelbach-Bruse, S., Fassunke, J., Kron, A., Scheel, A. H., Ihle, M. A., Heydt, C., Westphal, T., Weber, J. -P., Fischer, R. N., Riedel, R., Kaminsky, B., Draube, A., Rothe, A., Kambartel, K. -O., Hillmer, A., Buettner, R. and Wolf, J. (2020). KRAS mutations in never-smoker NSCLC patients: Defining a new patient subgroup. Oncol. Res. Treat., 43 (SUPPL 4). S. 139 - 140. BASEL: KARGER. ISSN 2296-5262

Sebastian, M., Reck, M., Fischer, R. N., Christoph, D. C. C., Bernhardt, C., von der Heyde, E., Nusch, A., Ludwig, P., Hipper, A., Hanselmann, J., Medinger, T., Binninger, A., Jaenicke, M., Christopoulos, P., Elender, C., Bethge, A., Seese, B., Gauler, T. C. and Waller, C. (2022). First real-world outcome data of SCLC in Germany: Data from the Clinical Research platform Into molecular testing, treatment and outcome of (non-)Small cell lung carcinoma Patients (CRISP; AIO-TRK-0315). Ann. Oncol., 33 (7). S. S1252 - 1. AMSTERDAM: ELSEVIER. ISSN 1569-8041

Weber, J. -P., Fischer, R. N., George, J., Scheel, A., Westphal, T., Koleczko, S., Nogova, L., Riedel, R., Michels, S., Scheffler, M., Abdullah, D. S. Y., Sueptitz, J., Keser, E., Merkelbach-Bruse, S., Pinto, A., Buettner, R., Thomas, R. and Wolf, J. (2020). Small Cell Lung Cancer - Filling the gap between science and patients. Oncol. Res. Treat., 43 (SUPPL 4). S. 154 - 155. BASEL: KARGER. ISSN 2296-5262

This list was generated on Thu Mar 28 18:29:23 2024 CET.